Dynavax to Present at the H.C. Wainwright Global Investment Conference

Rhea-AI Summary

Dynavax Technologies Corporation (Nasdaq: DVAX) announced its participation in the H.C. Wainwright Global Investment Conference from May 23-26, 2022. CEO Ryan Spencer will present at the event. The on-demand presentation will be accessible starting May 24, 2022, at 7:00 a.m. E.T., through the Company's website. Dynavax focuses on developing innovative vaccines, including the HEPLISAV-B® vaccine for Hepatitis B and CpG 1018 adjuvant used in COVID-19 vaccines. For more details, visit dynavax.com.

EMERYVILLE, Calif., May 16, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that Ryan Spencer, Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference, being held May 23-26, 2022.

The on demand presentation will be available, beginning Tuesday, May 24, 2022 at 7:00 a.m. E.T. and may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors.dynavax.com/events-presentations.

About Dynavax
Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S. and the European Union for the prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older, and CpG 1018 adjuvant, currently used in multiple adjuvanted COVID-19 vaccines. Dynavax is advancing CpG 1018 adjuvant as a premier vaccine adjuvant through global research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, seasonal influenza, universal influenza, plague, shingles and Tdap. For more information about our marketed products and development pipeline, visit www.dynavax.com and follow Dynavax on LinkedIn.

Contacts:
Nicole Arndt
narndt@dynavax.com
510-665-7264

Derek Cole, President
Investor Relations Advisory Solutions
derek.cole@IRadvisory.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/dynavax-to-present-at-the-hc-wainwright-global-investment-conference-301548166.html

SOURCE Dynavax Technologies

FAQ

When will Dynavax present at the H.C. Wainwright Global Investment Conference?

Dynavax will present at the H.C. Wainwright Global Investment Conference from May 23-26, 2022.

What time will the Dynavax presentation be available?

The on-demand presentation by Dynavax will be available starting May 24, 2022, at 7:00 a.m. E.T.

Who is presenting for Dynavax at the conference?

CEO Ryan Spencer will be presenting for Dynavax at the conference.

What products does Dynavax focus on?

Dynavax focuses on innovative vaccines, including HEPLISAV-B® for Hepatitis B and the CpG 1018 adjuvant for COVID-19 vaccines.

Where can I access the Dynavax presentation?

The Dynavax presentation can be accessed through the 'Events & Presentations' page in the Investors section of their website.